Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Gill

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Journal of the International AIDS Society|December 9, 2024
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohortBrenda Gati Mirembe, Deborah Donnell, Meighan Krows, et al.
BMJ Open|May 1, 2024
Novel point-of-care cytokine biomarker lateral flow test for the screening for sexually transmitted infections and bacterial vaginosis: study protocol of a multicentre multidisciplinary prospective observational clinical study to evaluate the performance and feasibility of the Genital InFlammation Test (GIFT)Stephanie Ramboarina, Tania Crucitti, Katherine Gill, et al.
The New England Journal of Medicine|July 24, 2024
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda-Gail Bekker, Moupali Das, Quarraisha Abdool Karim, et al.
Frontiers in Immunology|October 2, 2025
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCTSinead Delany-Moretlwe, Hakim-Moulay Dehbi, Izukanji Sikazwe, et al.
PLOS Global Public Health|December 5, 2024
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA studyNigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
PLOS Global Public Health|April 11, 2024
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
Nature Communications|October 6, 2025
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIVNonhlanhla N Mkhize, Bo Zhang, Caroline Brackett, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Journal of the International AIDS Society|December 9, 2024
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohortBrenda Gati Mirembe, Deborah Donnell, Meighan Krows, et al.
BMJ Open|May 1, 2024
Novel point-of-care cytokine biomarker lateral flow test for the screening for sexually transmitted infections and bacterial vaginosis: study protocol of a multicentre multidisciplinary prospective observational clinical study to evaluate the performance and feasibility of the Genital InFlammation Test (GIFT)Stephanie Ramboarina, Tania Crucitti, Katherine Gill, et al.
The New England Journal of Medicine|July 24, 2024
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda-Gail Bekker, Moupali Das, Quarraisha Abdool Karim, et al.
Frontiers in Immunology|October 2, 2025
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCTSinead Delany-Moretlwe, Hakim-Moulay Dehbi, Izukanji Sikazwe, et al.
PLOS Global Public Health|December 5, 2024
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA studyNigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
PLOS Global Public Health|April 11, 2024
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
Nature Communications|October 6, 2025
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIVNonhlanhla N Mkhize, Bo Zhang, Caroline Brackett, et al.
Pageof 8